Correlation Between Syndax Pharmaceuticals and Spyre Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Spyre Therapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Spyre Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Spyre Therapeutics

0.38
  Correlation Coefficient

Weak diversification

The 3 months correlation between Syndax and Spyre is 0.38. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Spyre Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to under-perform the Spyre Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Syndax Pharmaceuticals is 5.08 times less risky than Spyre Therapeutics. The stock trades about -0.01 of its potential returns per unit of risk. The Spyre Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  850.00  in Spyre Therapeutics on December 5, 2024 and sell it today you would earn a total of  972.00  from holding Spyre Therapeutics or generate 114.35% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Syndax Pharmaceuticals  vs.  Spyre Therapeutics

 Performance 
       Timeline  
Syndax Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Spyre Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Syndax Pharmaceuticals and Spyre Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Syndax Pharmaceuticals and Spyre Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.
The idea behind Syndax Pharmaceuticals and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Complementary Tools

Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope